News-Overview/June-2024

James C. Meehan, Jr., MD, 59, an ophthalmologist and functional medicine doctor, who was an outspoken critic of COVID-19 shot risks and failures, a brave vaccine choice advocate, and longtime...

The FDA's Vaccines and Related Biological Products Advisory Committee voted to recommend updating the COVID-19 vaccine to include a SARS-CoV-2 JN.1 lineage strain, citing the current vaccine's ineffectiveness against emerging variants. Despite the absence of safety data, the committee emphasized the importance of vaccine effectiveness, while noting the potential for rapid variant evolution which might impact vaccine efficacy. Manufacturers like Moderna, Pfizer, and Novavax presented promising data for their new vaccine candidates, with an emphasis on preparedness to meet the FDA's upcoming strain decision.